BRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Reuters12-10

Dec 10 (Reuters) - Arvinas :

* ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER SYMPOSIUM

* ARVINAS INC - VEPDEGESTRANT AND ABEMACICLIB SHOW 62.5% CLINICAL BENEFIT RATE

* ARVINAS INC - COMBINATION SHOWS CONSISTENT SAFETY PROFILE, NO SIGNIFICANT DRUG INTERACTION

* ARVINAS INC - RECOMMENDED PHASE 2 DOSE IS 200 MG QD VEPDEGESTRANT, 150 MG BID ABEMACICLIB

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490165980?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490165980","market":"us","top_or_hot":-1,"title":"BRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium","media":"Reuters","content":"<html><body><p>Dec 10 (Reuters) - Arvinas   :</p><p>   * ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER SYMPOSIUM</p><p>   * ARVINAS INC - VEPDEGESTRANT AND ABEMACICLIB SHOW 62.5% CLINICAL BENEFIT RATE</p><p>   * ARVINAS INC - COMBINATION SHOWS CONSISTENT SAFETY PROFILE, NO SIGNIFICANT DRUG INTERACTION</p><p>   * ARVINAS INC - RECOMMENDED PHASE 2 DOSE IS 200 MG QD VEPDEGESTRANT, 150 MG BID ABEMACICLIB</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-10 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dec 10 (Reuters) - Arvinas   :   * ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2490165980","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490165980","pubTimestamp":1733839639,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Dec 10  - Arvinas   :   * ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER SYMPOSIUM   * ARVINAS INC - VEPDEGESTRANT AND ABEMACICLIB SHOW 62.5% CLINICAL BENEFIT RATE   * ARVINAS INC - COMBINATION SHOWS CONSISTENT SAFETY PROFILE, NO SIGNIFICANT DRUG INTERACTION   * ARVINAS INC - RECOMMENDED PHASE 2 DOSE IS 200 MG QD VEPDEGESTRANT, 150 MG BID ABEMACICLIBSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","ARVN":"Arvinas Holding Company LLC","PFE":"辉瑞"},"translate_title":"简介-Arvinas和辉瑞在2024年圣安东尼奥乳腺癌研讨会上公布了Vepdegestrant联合Abemaciclib的Tactive-U子研究的初始1B期数据","themeId":"f51f112c51cad6fb01d7527bc545b26e","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"ARVN":0.9},"content_text":"Dec 10 (Reuters) - Arvinas   :   * ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER SYMPOSIUM   * ARVINAS INC - VEPDEGESTRANT AND ABEMACICLIB SHOW 62.5% CLINICAL BENEFIT RATE   * ARVINAS INC - COMBINATION SHOWS CONSISTENT SAFETY PROFILE, NO SIGNIFICANT DRUG INTERACTION   * ARVINAS INC - RECOMMENDED PHASE 2 DOSE IS 200 MG QD VEPDEGESTRANT, 150 MG BID ABEMACICLIBSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490165980"}